In the same manner, tumor patients carrying germline BRCA1/2 variants cannot accurately repair DNA damage following the administration of chemotherapy drugs and similar anti-tumor treatments, and as a result, may also have increased risk or elevated severity of adverse reactions. This evidence concerns the gene BRCA1 and neoplasm.